500009
Ambalal Sarabhai financials
- Market cap
- ₹320 Cr
- Sector
- Healthcare
What Ambalal Sarabhai does
Ambalal Sarabhai Enterprises operates primarily through subsidiaries, joint ventures and an associate company rather than direct manufacturing. Its group companies make Active Pharmaceutical Ingredients, finished dosage forms, effervescent and Vitamin-C products, and generic and veterinary pharmaceuticals for domestic and export markets. Other group companies manufacture molecular-diagnostic test kits and analytical/test-and-measuring instruments, while one division distributes broadcast and professional audio/video equipment for international brands in India.
Segments
- Pharmaceuticals - API & Finished Dosage Forms
- Effervescent & fermentation-based pharma products
- Molecular Diagnostics
- Analytical & Test/Measuring Instruments
- Broadcast & Professional AV distribution
- Subsidiaries, JVs & associate
- 8 subsidiaries, 2 joint ventures, 1 associate company
- Manufacturing plants
- API, effervescent and diagnostics plants clustered at Ranoli, Vadodara (Gujarat)
- Internationally registered pharma products (Asence)
- 100+
- IVD-approved molecular diagnostic tests (CoSara)
- 15+
- Business divisions (Systronics India)
- 2 (Systronics - analytical/test instruments; Telerad - broadcast/AV)
- USFDA-inspected/approved facilities
- Vovantis plant (Ranoli) and Synbiotics fermentation plant
Quarterly results
Q1 FY27: revenue up 8.0%, net profit down 51.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 45 | 46 | 65 | 40 | 44 −1% | 52 +13% | 65 +1% | 44 +8% |
| EBITDA | 3 | -1 | 5 | 1 | 0 −86% | 4 +683% | 6 +8% | 5 +212% |
| Net profit | 3 | 2 | -0 | 8 | -1 −121% | 4 +63% | 7 +2507% | 4 −52% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +26.7% 1Y
1Y: ₹31.89 on 10 Sept 2025 → ₹40.4. High ₹48.34 (10 Aug 2026), low ₹23.82 (27 Jan 2026).
Financials, as filed
Revenue grew 5.9% a year over 3 years, FY23 to FY26. Operating margin widened to 5.7%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹170 Cr | ₹174 Cr | ₹196 Cr | ₹202 Cr |
| Operating profit | ₹6 Cr | ₹4 Cr | ₹8 Cr | ₹12 Cr |
| Operating margin | 3.8% | 2.4% | 3.9% | 5.7% |
| Interest | ₹2 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| Depreciation | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| Net profit | ₹11 Cr | ₹7 Cr | ₹5 Cr | ₹18 Cr |
| Net margin | 6.6% | 3.8% | 2.5% | 8.8% |
| Cash from operations | ₹6 Cr | ₹9 Cr | ₹-18 Cr | ₹13 Cr |
| Free cash flow | ₹-15 Cr | ₹6 Cr | ₹-20 Cr | ₹7 Cr |
| ROCE | 11.0% | 7.0% | 9.0% | 12.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹77 Cr | ₹77 Cr | ₹77 Cr | ₹77 Cr | ₹77 Cr | ₹77 Cr |
| Reserves | ₹-3 Cr | ₹43 Cr | ₹54 Cr | ₹60 Cr | ₹71 Cr | ₹82 Cr |
| Borrowings | ₹28 Cr | ₹27 Cr | ₹45 Cr | ₹46 Cr | ₹47 Cr | ₹57 Cr |
| Other liabilities | ₹108 Cr | ₹84 Cr | ₹70 Cr | ₹67 Cr | ₹66 Cr | ₹65 Cr |
| Total liabilities | ₹210 Cr | ₹231 Cr | ₹246 Cr | ₹250 Cr | ₹260 Cr | ₹280 Cr |
| Fixed assets | ₹57 Cr | ₹58 Cr | ₹85 Cr | ₹88 Cr | ₹87 Cr | ₹89 Cr |
| Capital work in progress | ₹1 Cr | ₹12 Cr | ₹4 Cr | ₹0 Cr | ₹0 Cr | ₹4 Cr |
| Investments | ₹27 Cr | ₹33 Cr | ₹32 Cr | ₹29 Cr | ₹32 Cr | ₹32 Cr |
| Other assets | ₹125 Cr | ₹128 Cr | ₹125 Cr | ₹133 Cr | ₹141 Cr | ₹155 Cr |
| Total assets | ₹210 Cr | ₹231 Cr | ₹246 Cr | ₹250 Cr | ₹260 Cr | ₹280 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, FIIs trimmed −0.38 pp while the public added +0.38 pp. The shareholder count shrank 2% to 1,67,066.
- Promoters
- 31.4%
- Public
- 68.6%
Since Jun 2025
- FIIs −0.38 pp
- Public +0.38 pp
- Promoters +0.01 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 30.8%, Public 69.2%.Dec '23: Promoters 30.8%, Public 69.2%.Mar '24: Promoters 30.8%, Public 69.2%.Jun '24: Promoters 30.8%, Public 69.2%.Sep '24: Promoters 31.4%, Public 68.7%.Dec '24: Promoters 31.4%, DIIs 0.1%, Public 68.5%.Mar '25: Promoters 31.4%, FIIs 0.4%, DIIs 0.1%, Public 68.2%.Jun '25: Promoters 31.4%, FIIs 0.4%, Public 68.3%.Sep '25: Promoters 31.4%, FIIs 0.3%, Public 68.3%.Dec '25: Promoters 31.4%, FIIs 0.3%, Public 68.3%.Mar '26: Promoters 31.4%, Public 68.6%.Jun '26: Promoters 31.4%, Public 68.6%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Sarabhai Coeur Services Private Limited newly disclosed 0.12% held
The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Ambalal Sarabhai above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Sarabhai Holdings Private Limited | 25.77% | unchanged |
| Haryana Containers Limited | 2.28% | unchanged |
| Sharad Kanayalal Shah | 1.46% | unchanged |
| Yudhisthar Investments Pvt Ltd Ivl | 0.61% | unchanged |
| Koshalya Investments Pvt Ltd Ivl | 0.60% | unchanged |
| Kanda Investments Pvt.Ltd.(Ivl) | 0.27% | unchanged |
| Vasantbahar Investments Pvt.Ltd.(Ivl) | 0.26% | unchanged |
| Vaishakhi Investments Pvt.Ltd.(Ivl) | 0.24% | unchanged |
| Ashavari Investments Pvt.Ltd.(Ivl) | 0.24% | unchanged |
| Todirag Holdings Pvt.Ltd.(Ivl) | 0.24% | unchanged |
| Jonpuri Investments Pvt.Ltd.(Ivl) | 0.23% | unchanged |
| Madhavbag Holdings Pvt.Ltd.(Ivl) | 0.23% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Ambalal Sarabhai
Guides on how to read this kind of business and the numbers that matter.